Omecamtiv mecarbil is a selective, small-molecule activator of cardiac myosin that is being
developed as a potential treatment for heart failure with reduced ejection fraction. Here we …

Myosin is the indispensable molecular motor that utilizes chemical energy to produce force
for contraction within the cardiac myocyte. Myosin activity is gated by intracellular calcium …

The past decade has seen many advances in the management of heart failure (HF) that
have improved survival and quality of life for patients living with this condition. A number of …

Background: Omecamtiv mecarbil (OM) enhances systolic function in vivo by directly binding
the myosin cross-bridges (XBs) in the sarcomere. However, the mechanistic details …

Omecamtiv mecarbil (OM) is a myosin activator agent developed for the treatment of heart
failure. OM was reported to increase left ventricular ejection fraction and systolic ejection …

New promising avenues for the pharmacological treatment of skeletal and heart muscle
diseases rely on direct sarcomeric modulators, which are molecules that can directly bind to …

Introduction: Heart failure (HF) remains a major public health problem worldwide, affecting
approximately 23 million patients, and is predominantly a disease of the elderly population …

Abstract Purpose of Review This review aims to summarize the growing body of literature of
HF with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) with a …

Heart failure is well recognized as a major public health concern not only due to severe and
frequent adverse health outcomes but also related to the major financial burden this …

Purpose The need for novel approaches to cardiovascular drug development served as the
impetus to convene an open meeting of experts from the pharmaceutical industry and …